Mackenzie Financial
TVTX icon

Mackenzie Financial’s Travere Therapeutics TVTX Stock Holding History

Mackenzie Financial’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.46M Buy
166,571
+90,968
+120% +$4.03M 0.01% 659
2026
Q1 		$2.25M Buy
75,603
+34,213
+83% +$1.02M ﹤0.01% 900
2025
Q4 		$1.56M Sell
41,390
-8,980
-18% -$292K ﹤0.01% 941
2025
Q3 		$1.2M Sell
50,370
-9,933
-16% -$187K ﹤0.01% 1017
2025
Q2 		$892K Buy
+60,303
New +$1000K ﹤0.01% 1041

Other funds holding TVTX

Jupiter Topco
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Nomura Asset Management International
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mackenzie Financial's TVTX Position: Q2 2026 in Review

Mackenzie Financial increased its Travere Therapeutics (TVTX) stake by 120% in Q2 2026, buying an estimated $4.03M and bringing the position to 166,571 shares worth $9.46M. The position accounts for 0.01% of the portfolio, ranked #659.

Mackenzie Financial first reported a position in TVTX in Q2 2025 and has held it in 5 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Mackenzie Financial held 166,571 shares of Travere Therapeutics worth $9.46M as of Q2 2026.
  • Mackenzie Financial bought 90,968 Travere Therapeutics shares in Q2 2026, an estimated $4.03M.
  • Travere Therapeutics made up 0.01% of Mackenzie Financial's portfolio in Q2 2026, its #659 holding.
  • Mackenzie Financial first reported a position in Travere Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.